Lyell Immunopharma (LYEL) EBIT (2020 - 2026)
Lyell Immunopharma (LYEL) posted EBIT of -$44.3 million for Q1 2026, up 65.32% sequentially from -$127.6 million in Q4 2025, and up 22.85% YoY from -$36.0 million in Q1 2025.
Lyell Immunopharma (LYEL) EBIT (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported EBIT for 7 years, with the latest figure at -$44.3 million in Q1 2026.
- Quarterly EBIT rose 22.85% year-over-year to -$44.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$256.3 million (up 28.91% YoY) and the FY2025 annual result came in at -$269.4 million, up 24.91% from the prior year.
- EBIT advanced to -$44.3 million in Q1 2026 per LYEL's latest filing, from -$127.6 million in the prior quarter.
- Over five years, EBIT peaked at -$14.8 million in Q4 2022 and troughed at -$201.1 million in Q4 2024.
- A 5-year average of -$65.1 million and a median of -$57.4 million in 2025 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2023: EBIT soared 68.9% in 2022, then plunged 302.52% in 2023.
- Over 5 years, EBIT stood at -$14.8 million in 2022, then slumped by 302.52% to -$59.5 million in 2023, then plunged by 238.02% to -$201.1 million in 2024, then soared by 36.54% to -$127.6 million in 2025, then surged by 65.32% to -$44.3 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$44.3 million, -$127.6 million, and -$37.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | -47.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.34 Mn |
| Mar 31, 2026 | -44.26 Mn |
| Dec 31, 2025 | -127.64 Mn |
| Sep 30, 2025 | -37.25 Mn |
| Jun 30, 2025 | -47.14 Mn |
| Mar 31, 2025 | -57.37 Mn |
| Dec 31, 2024 | -201.15 Mn |
| Sep 30, 2024 | -50.51 Mn |
| Jun 30, 2024 | -51.53 Mn |
| Mar 31, 2024 | -55.58 Mn |
| Dec 31, 2023 | -59.51 Mn |
| Sep 30, 2023 | -59.04 Mn |
| Jun 30, 2023 | -65.91 Mn |
| Mar 31, 2023 | -62.56 Mn |
| Dec 31, 2022 | -14.78 Mn |
| Sep 30, 2022 | -66.44 Mn |
| Jun 30, 2022 | -37.26 Mn |
| Mar 31, 2022 | -68.58 Mn |
| Dec 31, 2021 | -47.54 Mn |
| Sep 30, 2021 | -49.16 Mn |